Kura Oncology/$KURA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kura Oncology
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
Ticker
$KURA
Sector
Primary listing
Employees
192
Headquarters
Website
Kura Oncology Metrics
BasicAdvanced
$842M
-
-$2.26
0.40
-
Price and volume
Market cap
$842M
Beta
0.4
52-week high
$18.00
52-week low
$5.41
Average daily volume
1.8M
Financial strength
Current ratio
6.159
Quick ratio
5.928
Long term debt to equity
4.801
Total debt to equity
6.374
Interest coverage (TTM)
-138.35%
Profitability
EBITDA (TTM)
-218.828
Gross margin (TTM)
-137.89%
Net profit margin (TTM)
-236.76%
Operating margin (TTM)
-263.82%
Effective tax rate (TTM)
-1.15%
Revenue per employee (TTM)
$430,000
Management effectiveness
Return on assets (TTM)
-22.93%
Return on equity (TTM)
-51.11%
Valuation
Price to revenue (TTM)
10.166
Price to book
2.76
Price to tangible book (TTM)
2.76
Price to free cash flow (TTM)
6.89
Free cash flow yield (TTM)
14.51%
Free cash flow per share (TTM)
1.408
Growth
Earnings per share change (TTM)
1.07%
3-year earnings per share growth (CAGR)
4.00%
What the Analysts think about Kura Oncology
Analyst ratings (Buy, Hold, Sell) for Kura Oncology stock.
Bulls say / Bears say
FDA’s acceptance of the NDA for ziftomenib with Priority Review and a PDUFA target action date of November 30, 2025, positions Kura one step closer to potential first-in-class approval for R/R NPM1-mutant AML (GlobeNewswire).
Positive data presented at the 2025 ASCO Annual Meeting showed a 23% CR + CRh rate for ziftomenib in the Phase 2 KOMET-001 trial, exceeding historical controls in heavily pretreated R/R NPM1-mutant AML patients (Kura Oncology Q2 Release).
Commercial preparations are advancing with completion of U.S. field sales team hiring and ongoing pre-approval stakeholder engagement, underscoring readiness for launch upon approval (Kura Oncology Q2 Release).
KURA shares hit a 52-week low of $5.65 on April 7, 2025, reflecting persistent investor skepticism despite clinical progress (Investing.com).
Q2 2025 GAAP revenue of $15.3 million missed expectations of $39.1 million, while net loss widened to $66.1 million, highlighting financial pressures before product commercialization (Nasdaq).
JMP Securities cut its price target from $28 to $24 on July 2, 2025, tempering upside expectations amid reassessment of Kura’s clinical-stage pipeline value (Ainvest).
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.
Kura Oncology Financial Performance
Revenues and expenses
Kura Oncology Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kura Oncology stock?
Kura Oncology (KURA) has a market cap of $842M as of October 25, 2025.
What is the P/E ratio for Kura Oncology stock?
The price to earnings (P/E) ratio for Kura Oncology (KURA) stock is 0 as of October 25, 2025.
Does Kura Oncology stock pay dividends?
No, Kura Oncology (KURA) stock does not pay dividends to its shareholders as of October 25, 2025.
When is the next Kura Oncology dividend payment date?
Kura Oncology (KURA) stock does not pay dividends to its shareholders.
What is the beta indicator for Kura Oncology?
Kura Oncology (KURA) has a beta rating of 0.4. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.